Latest Industry Insights

A team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.

Scripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr. Colette Saccomanno to learn more.

Technology Networks recently spoke with Bryan Witherbee, CEO, Ardaza, to learn more about ZIVA, a multiplex label-free biosensor platform, and discuss some of the applications it could benefit.

Our immune system is incredibly complex. Developing a complete understanding is an enormous undertaking but one to which scientists have been striving in order to advance disease understanding and improve treatments.

Technology Networks spoke with James Graham, Executive Director at Recce Pharmaceuticals, to learn more about how synthetic antibiotics differ from those derived from natural sources. He also discusses how the company has developed a novel class of synthetic antibiotics and elaborates on their mechanism of action.

Technology Networks recently spoke with David Younger, PhD, Co-founder and CEO of A-Alpha Bio, to learn more about how the company has harnessed synthetic biology and next-generation sequencing techniques to measure millions of interactions between proteins in a single test tube. This enables the identification of potential drugs for the treatment of infectious diseases, including COVID-19.

One of the COVID-19 vaccine candidates that received fast track designation by the FDA is mRNA-1273, developed by Moderna, a clinical stage biotechnology company. The company has shared the positive interim results from a Phase I clinical trial of the vaccine in The New England Journal of Medicine .

We spoke to Ari Goldfarb, CEO of Kando, about how their wastewater monitoring technology works and how it is being applied to the current monitoring efforts in the COVID-19 pandemic.

To discover how the strength of a person’s immune response to SARS-CoV-2 can be assessed, and why this is important, Technology Networks spoke with Andrew Makin, VP Medical Affairs, Oxford Immunotec.

The Innovative Genomics Institute (IGI) has launched an impressive COVID-19 diagnostic testing laboratory at UC Berkeley. Technology Networks spoke with Professor Jennifer Doudna, Executive Director at IGI and Professor of Molecular and Cell Biology and Chemistry at the University of California, Berkeley, to learn exactly how this ambitious effort has been achieved.